<DOC>
	<DOCNO>NCT01742637</DOCNO>
	<brief_summary>The objective study evaluate therapeutic equivalence safety Adapalene Benzoyl Peroxide 0.1 % /2.5 % Gel ( Taro Pharmaceuticals Inc. ) Epiduo® ( Adapalene Benzoyl Peroxide 0.1 % /2.5 % Gel ) ( Galderma Laboratories , L.P. ) treatment acne vulgaris , demonstrate superiority efficacy test reference product vehicle ( placebo ) control treatment acne vulgaris .</brief_summary>
	<brief_title>Study Comparing Adapalene Benzoyl Peroxide Gel 0.1 % /2.5 % Epiduo® Both Placebo Control Treatment Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene , Benzoyl Peroxide Drug Combination</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Healthy male non pregnant female age ≥ 12 ≤ 40 year clinical diagnosis acne vulgaris . Subjects 18 year age old must provide write informed consent . Subjects 12 17 year age must provide write assent , must accompany write informed consent subject 's legally acceptable representative . All subject legally acceptable representative must sign Health Insurance Portability Accountability Act authorization . Subjects must minimum ≥ 25 noninflammatory lesion ≥ 20 inflammatory lesion ≤ 2 nodulocystic lesion , baseline face . Subjects must definite clinical diagnosis acne vulgaris severity grade 2 , 3 , 4 per Investigator 's Global Assessment ( IGA ) . Subjects must willing refrain use topical acne medication antibiotic acne vulgaris 12week treatment period , investigational product . Female subject childbearing potential ( exclude surgically sterilize postmenopausal least 1 year ) , addition negative urine pregnancy test , must willing use acceptable form birth control study day first dose administration 30 day last administration study drug . All male subject must agree use accept method birth control partner , day first dose administration 30 day last administration study drug . Subjects must willing able understand comply requirement protocol . Subjects must good health free clinically significant disease , include limited , condition may interfere evaluation acne vulgaris . Subjects use makeup must use brands/types minimum period 14 day prior study entry must agree change brand/type frequency use throughout study . Female subject pregnant , nurse plan become pregnant study participation . Subjects history hypersensitivity allergy adapalene , retinoids and/or study medication ingredient , know hypersensitivity adapalene benzoyl peroxide excipients . Subjects presence skin condition would interfere diagnosis assessment acne vulgaris . Subjects excessive facial hair would interfere diagnosis assessment acne vulgaris . Subjects perform wax depilation face within 14 day prior baseline . Subjects use within 6 month prior baseline use study oral retinoids therapeutic Vitamin A supplement great 10,000 units/day . Subjects use estrogens oral contraceptive le 3 month prior baseline . Subjects use follow procedure face within 1 month prior baseline use study : cryodestruction chemodestruction , dermabrasion , photodynamic therapy , acne surgery , intralesional steroid , xray therapy . Subjects use follow treatment within 1 month prior baseline use study : systemic steroid , systemic antibiotic , systemic treatment acne vulgaris , systemic antiinflammatory agent . Subjects use follow treatment within 2 week prior baseline study : topical steroid , topical retinoids , αhydroxy/glycolic acid , benzoyl peroxide , topical antiinflammatory agent , topical antibiotic . Use spironolactone prohibit study . Use tan booth , sunbathe , excessive exposure sun prohibit study . Subjects receive radiation therapy and/or antineoplastic agent within 90 day prior baseline . Subjects unstable medical disorder clinically significant lifethreatening disease . Subjects ongoing malignancy require systemic treatment , subject malignancy skin facial area . Subjects engage activity involve excessive prolonged exposure sunlight weather extreme , wind cold . Subjects consume excessive amount alcohol use drug abuse . Subjects participate investigational drug study within 30 day prior baseline . Subjects previously enrol study . Subjects laser therapy , electrodesiccation phototherapy facial area within 180 day prior study entry . Subjects cosmetic procedure may affect efficacy safety profile investigational product within 14 day prior study entry . Cosmetic procedure facial prohibit throughout study . Subjects currently recently bacterial folliculitis face .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Acne Vulgaris</keyword>
	<keyword>Adapalene Benzoyl Peroxide Gel 0.1 % /2.5 %</keyword>
	<keyword>Epiduo®</keyword>
</DOC>